Der Gynäkologe

, Volume 51, Issue 4, pp 312–318 | Cite as

Therapeutische Konzepte bei habitueller Abortneigung

Viel hilft viel?
  • Kilian Vomstein
  • Katharina Feil
  • Ruben-J. Kuon
  • Bettina Toth
Leitthema
  • 68 Downloads

Zusammenfassung

Hintergrund

Nach der standardisierten diagnostischen Abklärung von Frauen mit habituellen Aborten (wiederkehrende Spontanaborte, WSA) sollte eine spezifische risikofaktoradaptierte Therapie eingeleitet werden. Bislang gibt es jedoch wenige evidenzbasierte Daten, welche eine klare Indikationsstellung für eine Therapieeinleitung bedingen.

Ziel der Arbeit

Welche therapeutischen Konzepte gibt es derzeit zur Behandlung von Frauen mit WSA?

Material und Methoden

Anhand der bestehenden Literatur, der aktuellen ESHRE(European Society of Human Reproduction and Embryology)-Leitlinie, „Guideline on the management of recurrent pregnancy loss“, und der S2k-Leitlinie der AWMF (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften), „Diagnostik und Therapie beim wiederholten Spontanabort“ (015/50), werden mögliche therapeutische Konzepte bei WSA dargelegt.

Ergebnisse

Eine Septumresektion sollte ebenso wie die Optimierung der Schilddrüsenfunktion (Zielwert TSH, Thyreoidea-stimulierendes Hormon, <2,5 mU/l) angeraten werden. Bei einem Antiphospholipidsyndrom (APLS) bzw. einem „non-criteria“ APLS ist eine Behandlung mit niedermolekularem Heparin und Acetylsalicylsäure indiziert, eine generelle prophylaktische Heparinisierung dagegen scheint obsolet. Immunologische Behandlungsoptionen werden derzeit nur unter Studienbedingungen empfohlen.

Diskussion

Die Betreuung von Paaren mit WSA stellt für jeden Frauenarzt eine besondere Herausforderung dar und bedarf einer intensiven Betreuung. Die aufgeführten Therapieoptionen orientieren sich an den Empfehlungen der nationalen und internationalen Leitlinien.

Schlüsselwörter

Niedermolekulares Heparin Antiphospholipidsyndrom Progesteron Antikoagulanzien Beratung 

Therapeutic concepts for recurrent miscarriage

The more, the better?

Abstract

Background

A risk factor-specific individualized treatment strategy to prevent recurrent miscarriage should be started after a standardized diagnostic work-up. There are few evidence-based data indicating which treatment should be chosen.

Objective

What are the therapeutic options in recurrent miscarriage and what is the evidence?

Material and methods

This review evaluates the most recent recommendations concerning therapeutic options for recurrent miscarriage based on the European Society of Human Reproduction and Embryology (ESHRE) guidelines on the management of recurrent pregnancy loss as well as the S2k guidelines of the Association of the Scientific Medical Societies in Germany (AWMF) on the diagnostics and therapy of recurrent miscarriage (015/50).

Results

A septum resection as well as optimization of the thyroid gland function with a target value for thyroid-stimulating hormone (TSH) of >2.5mU/l should be performed. While treatment of antiphospholipid syndrome (APLS) and the “non-criteria” APLS with low molecular weight heparin (LMWH) and acetylsalicylic acid is recommended, a general treatment with LMWH should not be performed. Immunomodulatory treatment options should currently only be carried out in clinical trials.

Conclusion

Counseling patients with recurrent miscarriage has become more challenging with many different therapeutic options evolving in recent years. Therapeutic strategies need scientific evidence and new treatment options should be performed in clinical trials. This review outlines the treatment options recommended by national and international guidelines.

Keywords

Heparin, low molecular weight Antiphospholipid syndrome Progesterone Anticoagulants Counseling 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

R.-J. Kuon und B. Toth sind Gesellschafter der Reprognostics GbR. K. Vomstein und K. Feil geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    ESHRE Early Pregnancy Guidline Development Group (2017) Recurrent pregnancy loss: guideline of the European Society of Human Reproduction and EmbryologyGoogle Scholar
  2. 2.
    RCOG (2011) The investigation and treatment of couples with recurrent first-trimester and second-trimester miscarriage. RCOG green-top guideline no 17. Royal College of Obstetricians & Gynaecologists, LondonGoogle Scholar
  3. 3.
    American College of Obstetricians and Gynecologists (2002) ACOG practice bulletin. Management of recurrent pregnancy loss. Number 24, February 2001. (Replaces Technical Bulletin Number 212, September 1995). American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 78(2):179–190CrossRefGoogle Scholar
  4. 4.
    ASRM Practice Committee (2012) Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril 98(5):1103–1111CrossRefGoogle Scholar
  5. 5.
    Rudnik-Schöneborn S, Swoboda M, Zschocke J (2018) Genetische Untersuchungen bei wiederholten Spontanaborten – Aktuelle Empfehlungen unter besonderer Berücksichtigung der Präimplantationsdiagnostik. Gynäkologe.  https://doi.org/10.1007/s00129-018-4205-9 Google Scholar
  6. 6.
    Salim R et al (2003) A comparative study of the morphology of congenital uterine anomalies in women with and without a history of recurrent first trimester miscarriage. Hum Reprod 18(1):162–166CrossRefPubMedGoogle Scholar
  7. 7.
    Valle RF, Ekpo GE (2013) Hysteroscopic metroplasty for the septate uterus: review and meta-analysis. J Minim Invasive Gynecol 20(1):22–42CrossRefPubMedGoogle Scholar
  8. 8.
    Kormanyos Z, Molnar BG, Pal A (2006) Removal of a residual portion of a uterine septum in women of advanced reproductive age: obstetric outcome. Hum Reprod 21(4):1047–1051CrossRefPubMedGoogle Scholar
  9. 9.
    Rikken JF et al (2017) Septum resection for women of reproductive age with a septate uterus. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.CD008576.pub4 PubMedGoogle Scholar
  10. 10.
    Ozgur K et al (2015) Perinatal outcomes in singleton and twin ICSI pregnancies following hysteroscopic correction of partial intrauterine septa. J Assist Reprod Genet 32(4):533–541CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Yang JH et al (2013) Optimal waiting period for subsequent fertility treatment after various hysteroscopic surgeries. Fertil Steril 99(7):2092–2096.e3CrossRefPubMedGoogle Scholar
  12. 12.
    Sugiura-Ogasawara M et al (2011) Uterine anomaly and recurrent pregnancy loss. Semin Reprod Med 29(6):514–521CrossRefPubMedGoogle Scholar
  13. 13.
    Jaslow CR (2014) Uterine factors. Obstet Gynecol Clin North Am 41(1):57–86CrossRefPubMedGoogle Scholar
  14. 14.
    Bailey AP, Jaslow CR, Kutteh WH (2015) Minimally invasive surgical options for congenital and acquired uterine factors associated with recurrent pregnancy loss. Womens Health 11(2):161–167Google Scholar
  15. 15.
    Bosteels J et al (2015) Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.CD009461.pub2 Google Scholar
  16. 16.
    Saravelos SH et al (2011) The prevalence and impact of fibroids and their treatment on the outcome of pregnancy in women with recurrent miscarriage. Hum Reprod 26(12):3274–3279CrossRefPubMedGoogle Scholar
  17. 17.
    Homer H, Saridogan E (2010) Uterine artery embolization for fibroids is associated with an increased risk of miscarriage. Fertil Steril 94(1):324–330CrossRefPubMedGoogle Scholar
  18. 18.
    Luyckx M et al (2014) First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. Fertil Steril 102(5):1404–1409CrossRefPubMedGoogle Scholar
  19. 19.
    Salim S et al (2011) Diagnosis and management of endometrial polyps: a critical review of the literature. J Minim Invasive Gynecol 18(5):569–581CrossRefPubMedGoogle Scholar
  20. 20.
    Lieng M et al (2009) Prevalence, 1‑year regression rate, and clinical significance of asymptomatic endometrial polyps: cross-sectional study. J Minim Invasive Gynecol 16(4):465–471CrossRefPubMedGoogle Scholar
  21. 21.
    Conforti A et al (2013) The management of Asherman syndrome: a review of literature. Reprod Biol Endocrinol 11:118CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Nigro G et al (2011) Role of the infections in recurrent spontaneous abortion. J Matern Fetal Neonatal Med 24(8):983–989CrossRefPubMedGoogle Scholar
  23. 23.
    Ng SC et al (2002) Expression of intracellular Th1 and Th2 cytokines in women with recurrent spontaneous abortion, implantation failures after IVF/ET or normal pregnancy. Am J Reprod Immunol 48(2):77–86CrossRefPubMedGoogle Scholar
  24. 24.
    Ugwumadu A et al (2003) Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet 361(9362):983–988CrossRefPubMedGoogle Scholar
  25. 25.
    Johnston-MacAnanny EB et al (2010) Chronic endometritis is a frequent finding in women with recurrent implantation failure after in vitro fertilization. Fertil Steril 93(2):437–441CrossRefPubMedGoogle Scholar
  26. 26.
    McQueen DB et al (2015) Pregnancy outcomes in women with chronic endometritis and recurrent pregnancy loss. Fertil Steril 104(4):927–931CrossRefPubMedGoogle Scholar
  27. 27.
    Cicinelli E et al (2015) Prevalence of chronic endometritis in repeated unexplained implantation failure and the IVF success rate after antibiotic therapy. Hum Reprod 30(2):323–330CrossRefPubMedGoogle Scholar
  28. 28.
    Melamed N, Hod M (2009) Perinatal mortality in pregestational diabetes. Int J Gynaecol Obstet 104(Suppl 1):S20–4CrossRefPubMedGoogle Scholar
  29. 29.
    Kleinwechter H et al (2014) Diabetes und Schwangerschaft – Evidenzbasierte Leitlinie der Deutschen Diabetes-Gesellschaft. AWMF, BerlinGoogle Scholar
  30. 30.
    Palomba S et al (2009) Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril 92(5):1646–1658CrossRefPubMedGoogle Scholar
  31. 31.
    Jakubowicz DJ et al (2002) Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 87(2):524–529CrossRefPubMedGoogle Scholar
  32. 32.
    Hahn KA et al (2014) Body size and risk of spontaneous abortion among danish pregnancy planners. Paediatr Perinat Epidemiol 28(5):412–423CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Benhadi N et al (2009) Higher maternal TSH levels in pregnancy are associated with increased risk for miscarriage, fetal or neonatal death. Eur J Endocrinol 160(6):985–991CrossRefPubMedGoogle Scholar
  34. 34.
    Abramson J, Stagnaro-Green A (2001) Thyroid antibodies and fetal loss: an evolving story. Thyroid 11(1):57–63CrossRefPubMedGoogle Scholar
  35. 35.
    Nelson DB et al (2014) Subsequent pregnancy outcomes in women previously diagnosed with subclinical hypothyroidism. Am J Perinatol 31(1):77–84PubMedGoogle Scholar
  36. 36.
    Thangaratinam S et al (2011) Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence. BMJ 342:d2616CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Negro R, Mestman JH (2011) Thyroid disease in pregnancy. Best Pract Res Clin Endocrinol Metab 25(6):927–943CrossRefPubMedGoogle Scholar
  38. 38.
    De Groot L et al (2012) Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97(8):2543–2565CrossRefPubMedGoogle Scholar
  39. 39.
    Practice Committee of the American Society for Reproductive Medicine (2015) Current clinical irrelevance of luteal phase deficiency: a committee opinion. Fertil Steril 103(4):e27–32CrossRefGoogle Scholar
  40. 40.
    ASRM (2012) Practice Comittee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril 98(5):1103–1111CrossRefGoogle Scholar
  41. 41.
    Wischmann T (2018) Psychologische Aspekte bei Frühabort. Gynäkologe.  https://doi.org/10.1007/s00129-017-4180-6 Google Scholar
  42. 42.
    Empson M et al (2002) Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 99(1):135–144PubMedGoogle Scholar
  43. 43.
    Mak A et al (2010) Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford) 49(2):281–288CrossRefGoogle Scholar
  44. 44.
    Ziakas PD, Pavlou M, Voulgarelis M (2010) Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol 115(6):1256–1262CrossRefPubMedGoogle Scholar
  45. 45.
    Toth B et al (2015) Recurrent miscarriage: diagnostic and therapeutic procedures. Guideline of the DGGG (S1-level, AWMF registry no. 015/050, december 2013). Geburtshilfe Frauenheilkd 75(11):1117–1129CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Cohn DM et al (2010) Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancy. J Thromb Haemost 8(10):2208–2213CrossRefPubMedGoogle Scholar
  47. 47.
    Tursi A et al (2008) Effect of gluten-free diet on pregnancy outcome in celiac disease patients with recurrent miscarriages. Dig Dis Sci 53(11):2925–2928CrossRefPubMedGoogle Scholar
  48. 48.
    Gomaa MF et al (2014) Combined oral prednisolone and heparin versus heparin: the effect on peripheral NK cells and clinical outcome in patients with unexplained recurrent miscarriage. A double-blind placebo randomized controlled trial. Arch Gynecol Obstet 290(4):757–762CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Fawzy M et al (2008) Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. Arch Gynecol Obstet 278(1):33–38CrossRefPubMedGoogle Scholar
  50. 50.
    Tempfer CB et al (2006) A combination treatment of prednisone, aspirin, folate, and progesterone in women with idiopathic recurrent miscarriage: a matched-pair study. Fertil Steril 86(1):145–148CrossRefPubMedGoogle Scholar
  51. 51.
    Tang AW et al (2013) A feasibility trial of screening women with idiopathic recurrent miscarriage for high uterine natural killer cell density and randomizing to prednisolone or placebo when pregnant. Hum Reprod 28(7):1743–1752CrossRefPubMedGoogle Scholar
  52. 52.
    Granato D et al (2000) Effects of parenteral lipid emulsions with different fatty acid composition on immune cell functions in vitro. Jpen J Parenter Enteral Nutr 24(2):113–118CrossRefPubMedGoogle Scholar
  53. 53.
    Roussev RG, Ng SC, Coulam CB (2007) Natural killer cell functional activity suppression by intravenous immunoglobulin, intralipid and soluble human leukocyte antigen-G. Am J Reprod Immunol 57(4):262–269CrossRefPubMedGoogle Scholar
  54. 54.
    Roussev RG et al (2008) Duration of intralipid’s suppressive effect on NK cell’s functional activity. Am J Reprod Immunol 60(3):258–263CrossRefPubMedGoogle Scholar
  55. 55.
    Roussev RG et al (2013) Preimplantation factor inhibits circulating natural killer cell cytotoxicity and reduces CD69 expression: implications for recurrent pregnancy loss therapy. Reprod Biomed Online 26(1):79–87CrossRefPubMedGoogle Scholar
  56. 56.
    Mayer K et al (2003) Short-time infusion of fish oil-based lipid emulsions, approved for parenteral nutrition, reduces monocyte proinflammatory cytokine generation and adhesive interaction with endothelium in humans. J Immunol 171(9):4837–4843CrossRefPubMedGoogle Scholar
  57. 57.
    Coulam CB, Acacio B (2012) Does immunotherapy for treatment of reproductive failure enhance live births? Am J Reprod Immunol 67(4):296–304CrossRefPubMedGoogle Scholar
  58. 58.
    Moraru M et al (2012) Intravenous immunoglobulin treatment increased live birth rate in a Spanish cohort of women with recurrent reproductive failure and expanded CD56(+) cells. Am J Reprod Immunol 68(1):75–84CrossRefPubMedGoogle Scholar
  59. 59.
    Meng L et al (2016) Effectiveness and potential mechanisms of intralipid in treating unexplained recurrent spontaneous abortion. Arch Gynecol Obstet 294(1):29–39CrossRefPubMedGoogle Scholar
  60. 60.
    Stephenson MD et al (2010) Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebo-controlled trial. Hum Reprod 25(9):2203–2209CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Ata B et al (2011) A systematic review of intravenous immunoglobulin for treatment of unexplained recurrent miscarriage. Fertil Steril 95(3):1080–1085.e1–2CrossRefPubMedGoogle Scholar
  62. 62.
    Ensom MH, Stephenson MD (2011) A two-center study on the pharmacokinetics of intravenous immunoglobulin before and during pregnancy in healthy women with poor obstetrical histories. Hum Reprod 26(9):2283–2288CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Winger EE, Reed JL (2008) Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol 60(1):8–16CrossRefPubMedGoogle Scholar
  64. 64.
    Clark P et al (2010) SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood 115(21):4162–4167CrossRefPubMedGoogle Scholar
  65. 65.
    Kaandorp SP et al (2010) Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 362(17):1586–1596CrossRefPubMedGoogle Scholar
  66. 66.
    Schleussner E, Petroff D (2015) Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss. Ann Intern Med 163(6):485CrossRefPubMedGoogle Scholar
  67. 67.
    Rodger MA et al (2016) Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet 388(10060):2629–2641CrossRefPubMedGoogle Scholar
  68. 68.
    de Jong PG, Goddijn M, Middeldorp S (2013) Antithrombotic therapy for pregnancy loss. Hum Reprod Update 16(6):656–673.  https://doi.org/10.1093/humupd/dmt019 CrossRefGoogle Scholar
  69. 69.
    Check JH (2012) The use of heparin for preventing miscarriage. Am J Reprod Immunol 67(4):326–333CrossRefPubMedGoogle Scholar
  70. 70.
    Gris JC (2011) LMWH have no place in recurrent pregnancy loss: debate-against the motion. Thromb Res 127(Suppl 3):S110–2CrossRefPubMedGoogle Scholar
  71. 71.
    de Jong PG et al (2015) ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia—study protocol for a randomized controlled trial. Trials 16:208CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Rolnik DL et al (2017) Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 377(7):613–622CrossRefPubMedGoogle Scholar
  73. 73.
    de Jong PG et al (2014) Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.CD004734.pub4 PubMedGoogle Scholar
  74. 74.
    Schisterman EF et al (2014) Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial. Lancet 384(9937):29–36CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Kilian Vomstein
    • 1
  • Katharina Feil
    • 1
  • Ruben-J. Kuon
    • 2
  • Bettina Toth
    • 1
  1. 1.Gynäkologische Endokrinologie und ReproduktionsmedizinMedizinische Universität InnsbruckInnsbruckÖsterreich
  2. 2.Abteilung für Gynäkologische Endokrinologie und FertilitätsstörungenUniversitätsfrauenklinik HeidelbergHeidelbergDeutschland

Personalised recommendations